The mission of the Michigan Cancer Research Consortium (MCRC) is to improve the oncologic health of the communities served by assuring patient access to and participation in state-of-the-art clinical trials and cancer prevention and control activities while contributing to knowledge development in the field of oncology care. The MCRC represents a proven resource with significant potential to serve the objectives of the National Cancer Institute's CCOP program. First funded in 1994 as a single component CCOP, it is now comprised of nine health systems and 120+ investigators from 35+ practices, covering the southeast quadrant of Michigan. Annual accrual exceeds 500+ credits to cancer treatment and prevention/control trials. There are currently 2,492 patients in follow-up. This grant application encompasses and articulates an ever-expanding vision for the Michigan Cancer Research Consortium. Support of and participation in NCI efforts toTevamp the clinical trials network in order to expand translational research and facilitate collaborative team science will be vital to MCRC's future. During the previous grant cycle, the MCRC proved a leader in the development of a web-based program for clinical trials administration, patient scheduling, and investigational drug inventory management. Of importance during this upcoming grant cycle will be the MCRC's continued focus on utilization of technology to maximize efficiencies in access, screening and recruitment to clinical trials. Continuous improvement in efficiencies include further centralization of CCOP administrative activities, e.g., implementation of central hiring and training. The MCRC has systems and relationships in place to foster increases in accrual to both treatment and prevention trials. It is ideally positioned to expand minority participation via a network of community organizations throughout its service area. Over a short 12-year period, the MCRC has become a leader in the NCI's CCOP program. The MCRC investigators and research staff are committed to its ongoing growth and achievement of objectives for the betterment of community cancer care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA063848-18
Application #
8080375
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Whitman, Cynthia B
Project Start
1994-08-05
Project End
2012-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
18
Fiscal Year
2011
Total Cost
$1,472,436
Indirect Cost
Name
Saint Joseph Mercy Health System
Department
Type
DUNS #
807606249
City
Ann Arbor
State
MI
Country
United States
Zip Code
48106
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Crozier, Jennifer A; Advani, Pooja P; LaPlant, Betsy et al. (2016) N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. Clin Breast Cancer 16:23-30

Showing the most recent 10 out of 153 publications